A7RC peptide modified paclitaxel liposomes dually target breast cancer
Authors:
- 20 August 2015
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 3 (12) , 1545-1554
Abstract
A7R peptide (ATWLPPR), a ligand of the NRP-1 receptor, regulates the intracellular signal transduction related to tumor vascularization and tumor growth. Here, we designed A7R-cysteine peptide (A7RC) surface modified paclitaxel liposomes (A7RC-LIPs) to achieve targeting delivery and inhibition of tumor growth and angiogenesis simultaneously. The cytotoxicity, inhibiting angiogenesis, and internalization of various liposomes by cells were assessed in vitro to confirm the influence of the peptide modification. The accumulations of A7RC-LIPs in various xenografts in mice were tracked to further identify the function of the peptide on the liposomes’ surface. The results confirmed that A7RC peptides could enhance the uptake of vesicles by MDA-MB-231 cells, leading to stronger cytotoxicity in vitro and higher accumulation of vesicles in MDA-MB-231 xenografts in vivo. In addition, A7RC peptides enhanced the inhibitory effects of LIPs on the HUVEC tubular formation on Matrigel. The A7RC-LIPs may be promising drug carriers for anticancer therapy.Keywords
This publication has 58 references indexed in Scilit:
- In vivo and ex vivo proofs of concept that cetuximab conjugated vitamin E TPGS micelles increases efficacy of delivered docetaxel against triple negative breast cancerBiomaterials, 2015
- Liposomes modified with P-aminophenyl-α-d-mannopyranoside: A carrier for targeting cerebral functional regions in miceEuropean Journal of Pharmaceutics and Biopharmaceutics, 2013
- Weekly paclitaxel in patients with recurrent or metastatic head and neck cancerCancer Chemotherapy and Pharmacology, 2010
- How do anti-mitotic drugs kill cancer cells?Journal of Cell Science, 2009
- Paclitaxel in Cancer Treatment: Perspectives and Prospects of its Delivery ChallengesCritical Reviews™ in Therapeutic Drug Carrier Systems, 2009
- Voriconazole into PLGA nanoparticles: Improving agglomeration and antifungal efficacyInternational Journal of Pharmaceutics, 2008
- Recent Developments in Taxane Drug DeliveryCurrent Drug Delivery, 2008
- Paclitaxel: a review of adverse toxicities and novel delivery strategiesExpert Opinion on Drug Safety, 2007
- Paclitaxel (Taxol)New England Journal of Medicine, 1995
- Hypersensitivity reactions from taxol.Journal of Clinical Oncology, 1990